iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine

Launched by RADBOUD UNIVERSITY MEDICAL CENTER · Jan 29, 2024

Keywords

ClinConnect Summary

This clinical trial, titled "iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine," is exploring a new way to see if someone has a lung infection caused by a fungus called Aspergillus. This infection can be difficult to diagnose because it often requires uncomfortable tests like taking samples from the lungs. The researchers are testing a method using a special imaging technique called PET/CT, which can help find the infection without needing invasive procedures. The hope is that this method, which uses a radioactive substance that sticks to the infection, can also tell the difference between an Aspergillus infection and cancer.

To participate in this trial, you need to be at least 18 years old and have symptoms that suggest you might have chronic pulmonary aspergillosis or allergic bronchopulmonary aspergillosis. You should not be pregnant, have severe kidney problems, or have received antifungal treatment in the last two days before the study. If you decide to take part, you will only need to visit the study site once for the imaging procedure. This trial is not yet recruiting participants, but it aims to find a less invasive way to diagnose this serious condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. The patient is at least 18 years old on the day of inclusion.
• • 2. The patient has suspected chronic pulmonary aspergillosis or ABPA.
• • 3. There is no significant interference with standard care and follow-up.
• Exclusion Criteria:
• • 1. The patient is pregnant or planning on becoming pregnant.
• • 2. The patient has severe kidney dysfunction with eGFR \< 30 ml/min/kg and/or receives dialysis.
• • 3. The patient has (chronic) iron overload.
• • 4. The patient has been receiving antifungal treatment for more than 48 hours prior to the study day.
• • 5. The patient is not able to lie still in the scanner.